GSK news

Today, GlaxoSmithKline announced the results of a Phase III study demonstrating that pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo.

GSK and Genmab A/S announced that the US FDA ODAC voted 10 to three that the Arzerra™ (ofatumumab) data are reasonably likely to predict clinical benefit for patients with chronic lymphocytic leukemia (CLL) whose disease is refractory to fludarabine and alemtuzumab.

GSK announced today that the US Department of Health and Human Services (HHS) has placed initial orders for A (H1N1) influenza vaccine antigen and the company’s proprietary adjuvant system, AS03, to support its pandemic influenza preparation efforts.

GSK is committed to supporting governments and health authorities around the world to respond to the emergence of the new A (H1N1) influenza strain.

GlaxoSmithKline plc (GSK) today announced that it has agreed to extend its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen) and to acquire a 16% shareholding in the South African based pharmaceuticals company.

Key results from three important studies of the cervical cancer vaccine, Cervarix®, will be available as of today at the 25th International Papillomavirus Conference (IPV) in Malmö, Sweden.

GSK today announced that it has entered into an agreement to divest full commercial rights to Wellbutrin XL® in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation, for $510 million (£340 million).

GlaxoSmithKline (GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain.

Primary endpoint achieved in REDUCE study as presented at American Urological Association

GlaxoSmithKline (GSK) is closely monitoring the situation regarding the emergence of a new influenza A (H1N1) strain in Mexico, the United States of America, Canada, France, Spain and New Zealand.